Studies Highlight New Therapies and Immunotherapies in Blood Cancer Treatment
New approaches, including targeted therapies and immunotherapies, are proving to be effective alternatives to traditional chemotherapy for treating blood cancers, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
These studies demonstrate the potential of therapies that can offer similar or better outcomes with reduced toxicity, leading to improved quality of life for patients.
**Azacitidine and Venetoclax Combination Outperforms Standard Care in Acute Myeloid Leukemia (AML)
**A phase 2 study compared azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed, fit adults with AML. The results showed that the azacitidine-venetoclax combination (aza-ven) improved event-free survival and overall response rates compared to standard care.
**Epcoritamab and Rituximab/Lenalidomide Combination for Follicular Lymphoma
A new trial found that a combination of epcoritamab, a bispecific antibody, and rituximab/lenalidomide, an immunotherapeutic combination, resulted in robust and lasting responses in patients with relapsed or refractory follicular lymphoma, offering a promising chemotherapy-free alternative.
**Pirtobrutinib vs. Ibrutinib for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
A phase III study compared pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, to ibrutinib, a covalent BTK inhibitor, in patients with CLL or SLL. Pirtobrutinib demonstrated non-inferiority in overall response rate, suggesting it is a viable option for both treatment-naive and relapsed/refractory patients.
**Chemotherapy-Free Approach for Ph+ Acute Lymphoblastic Leukemia (ALL)
A phase III trial compared a chemotherapy-free combination of ponatinib and blinatumomab to a targeted therapy and chemotherapy combination in newly diagnosed adult patients with Ph+ ALL. The results showed that the chemo-free approach significantly reduced the rate of death and increased the rate of complete remission, offering a promising alternative to traditional chemotherapy.
